MAPT and Alzheimer disease: Subtle cognitive changes may already emerge in the preclinical stage of Alzheimer’s disease (AD), that is, in cognitively unimpaired individuals with abnormal levels of biomarkers indicative of AD pathology, such as amyloid-β (Aβ) and tau (clinical stage 2 according to ref. 1).